[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"melasma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:melasma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,44,74,102,128,151,176,201,226,249,272,294,315,336,356,382,402,422,445,469,490],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645197","a-clinical-study-to-evaluate-the-efficacy-in-improving-dark-spots-after-8-weeks-of-use-of-facial-sunscreens-in-adult-participants-100645197",false,"NCT07679945","A Clinical Study to Evaluate the Efficacy in Improving Dark Spots After 8 Weeks of Use of Facial Sunscreens in Adult Participants","A Monocentric and Open-Label Clinical Study to Evaluate the Efficacy in Improving Dark Spots After 8 Weeks of Use of Facial Sunscreens in Adult Research Participants","El Porto Ex-US","Inclusion Criteria:\n\n1. Able to understand and follow study instructions\n2. Fitzpatrick skin types I-VI\n3. Presence of facial hyperpigmentation, such as:\n\n   * Mild to moderate melasma, or\n   * Visible dark spots (e.g., solar lentigines or post-inflammatory hyperpigmentation)\n4. Willing to comply with study procedures and product use\n5. For subjects in applicable groups: willing to use assigned sunscreen product\n\nExclusion Criteria:\n\n1. Known sensitivity or allergy to cosmetic or skincare products\n2. Skin conditions or lesions in the study area that could interfere with evaluation (e.g., active dermatitis, infections, significant irritation, or extensive scarring)\n3. Use of medications or products that may interfere with study evaluations\n4. Recent cosmetic or dermatological procedures in the study area (e.g., chemical peels, laser treatments, invasive procedures)\n5. Excessive sun exposure or use of tanning beds immediately prior to or during the study\n6. Pregnancy or intention to become pregnant during the study\n7. Participation in another clinical study within a recent period\n8. Any condition or situation that, in the investigator's judgment, may interfere with study participation or evaluation of results",true,"ALL","18 Years",{"count":21,"type":22},152,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study aims to evaluate the efficacy of a facial sunscreen under two experimental conditions-untinted and tinted-in improving facial spots (melasma and solar lentigines\u002Fpost-inflammatory hyperpigmentation) after 8 weeks of product use under normal conditions by adult participants.",[28,29,30],"Post-inflammatory Hyperpigmentation","Melasma","Solar Lentigo","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2026-06-02",{"date":39,"type":22},"2026-09-25",{"name":41,"class":42},"Kenvue Brands LLC","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100638862","comparative-efficacy-of-intralesional-tranexamic-acid-versus-mandelic-acid-peel-in-the-treatment-of-melasma-100638862","NCT07604844","Comparative Efficacy of Intralesional Tranexamic Acid Versus Mandelic Acid Peel in the Treatment of Melasma","Inclusion Criteria:\n\nAge 18-45 years. Clinical diagnosis of facial melasma. Fitzpatrick skin phototypes III-V. Disease duration of at least 3 months.\n\nExclusion Criteria:\n\nPregnancy or lactation. Known hypersensitivity to tranexamic acid or mandelic acid. Active facial dermatoses or infection. Personal or family history of thromboembolic disease. Coagulation disorders. Systemic retinoid use within 6 months. Oral contraceptive or hormone replacement therapy within 6 months. Use of topical or systemic depigmenting agents within 4 weeks. History of keloid tendency.","45 Years",{"count":52,"type":22},120,[25],"Melasma is a chronic acquired disorder of facial hyperpigmentation that significantly affects quality of life. Both intralesional tranexamic acid and mandelic acid chemical peels are effective treatment options with favorable safety profiles in darker skin types. However, comparative evidence in South Asian populations is limited. This study aims to compare the efficacy, safety, quality of life outcomes, and patient satisfaction of intralesional tranexamic acid versus mandelic acid peel in patients with facial melasma treated at Combined Military Hospital Abbottabad.",[29],[29,57,58,59,60,61,62],"Tranexamic Acid","Mandelic Acid","Chemical Peel","Hyperpigmentation","MELASQoL","Pakistan","NOT_YET_RECRUITING","2026-05-24",{"date":66,"type":35},"2026-05-28",{"date":68,"type":22},"2026-05",{"date":70,"type":22},"2026-10",{"name":72,"class":73},"Combined Military Hospital Abbottabad","OTHER",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":81,"minAge":19,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":43},"100634516","injectable-platelet-rich-fibrin-versus-intradermal-tranexamic-acid-for-melasma-100634516","NCT07540702","Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for Melasma","Assessment of Efficacy and Safety of Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid in the Treatment of Melasma: A Randomized Split-Face Study","Inclusion Criteria:\n\n* Clinical diagnosis of bilateral symmetrical facial melasma (epidermal or mixed type)\n* Female participants aged 18 to 50 years\n* Fitzpatrick skin types III to IV\n* Mild to moderate facial melasma\n* No melasma-specific treatment within the previous 4 weeks\n* No facial procedures, including peeling, laser resurfacing, or microneedling, within the previous 3 months\n* Willing and able to provide written informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Bleeding or coagulation disorders\n* Use of anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), or hormonal contraception\n* Active skin infection or facial inflammation\n* History of keloids or Koebner-prone conditions, such as psoriasis or vitiligo\n* Uncontrolled systemic disease, such as diabetes mellitus or autoimmune disease","FEMALE","50 Years",{"count":5,"type":22},[25],"Melasma is a chronic acquired hyperpigmentation disorder that commonly affects the face and has a significant impact on quality of life. Available treatments may improve pigmentation, but relapse is common and response can be variable.\n\nThis randomized split-face interventional study aims to compare the efficacy and safety of injectable platelet-rich fibrin (i-PRF) versus intradermal tranexamic acid (TA) in the treatment of facial melasma. Adult female patients with bilateral symmetrical facial melasma will be enrolled. In each participant, one side of the face will be randomly assigned to receive i-PRF and the contralateral side will receive intradermal TA.\n\nPatients will undergo five treatment sessions at 2-week intervals. Clinical response will be assessed using the modified Melasma Area and Severity Index (mMASI), Antera 3D camera measurements, Physician Global Assessment, patient satisfaction, and Melasma Quality of Life (MelasQoL) questionnaire. Safety will be evaluated by recording adverse events such as pain, tenderness, erythema, swelling, infection, ecchymosis, and hematoma.\n\nThe study is designed to determine whether i-PRF is an effective and safe treatment option for melasma compared with intradermal tranexamic acid.",[29,87],"Facial Melasma",[89,90,91,29,92],"Injectable platelet-rich fibrin","i-PRF","Tranexamic acid","Split-face study","2026-04-18",{"date":95,"type":35},"2026-04-22",{"date":97,"type":35},"2026-02-01",{"date":99,"type":22},"2026-10-01",{"name":101,"class":73},"Kasr El Aini Hospital",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":81,"minAge":19,"maxAge":82,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100633694","clinical-efficacy-and-mechanisms-of-a-topical-azone-tranexamic-acid-aloe-polysaccharide-gel-in-the-treatment-of-melasma-100633694","NCT07530016","Clinical Efficacy and Mechanisms of a Topical Azone-Tranexamic Acid-Aloe Polysaccharide Gel in the Treatment of Melasma","Melasma is a Common Pigmented Skin Disease, Related to Genetics and Ultraviolet Rays, and Prone to Causing Psychological Problems. The Current Treatments Have Limitations. The Combination Gel of Tranexamic Acid, Aloe Polysaccharide and Lauric Azonide is Expected to Enhance Efficacy and Reduce Side Effects. This Study Explores Its Therapeutic Effect and Mechanism, Providing New Strategies.","Inclusion Criteria:\n\nAdult patients aged 18-50 years diagnosed with melasma Famale\n\nExclusion Criteria:\n\n* Patients with contraindications to melatonin, including pregnancy, breastfeeding, autoimmune disorders, bleeding disorders, and diabetes, or contraindications to tranexamic acid, including thromboembolic events, history of thrombosis, renal impairment, and pregnancy or breastfeeding.\n\nPatients with a history of hypersensitivity to any of the medications. Patients already taking treatment of melasma",{"count":110,"type":22},10,[25],"Melasma is a common pigmentation disorder among young and middle-aged women, characterized by symmetrical brown-black patches on the face. It is related to genetics, ultraviolet radiation, endocrine factors and inflammation, and can lead to psychological problems and affect quality of life. Current treatments such as hydroquinone stimulation, laser therapy, and oral tranexamic acid have a high recurrence rate and poor compliance. The new gel formulation, which combines tranexamic acid (to inhibit tyrosinase), aloe polysaccharides (anti-inflammatory and repair), and lauric azon (promotes penetration), is expected to enhance efficacy and reduce side effects. This study aims to explore its clinical efficacy and synergistic mechanism, providing new strategies for the treatment of Melasma.",[29,114,57,115],"Treatment of Stable Melasma","Laurocapram",[117,118],"Improve transdermal efficiency","Treatment of stable melasma","2026-04-08",{"date":121,"type":35},"2026-04-14",{"date":123,"type":22},"2026-08-12",{"date":125,"type":22},"2028-11-16",{"name":127,"class":73},"The First Affiliated Hospital of Xinxiang Medical College",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100633138","phase-4-comparison-between-efficacy-of-topical-tranexamic-acid-vs-topical-ethyl-ascorbic-acid-in-treatment-of-melasma-100633138","NCT07522788","Comparison Between Efficacy of Topical Tranexamic Acid Vs Topical Ethyl Ascorbic Acid In Treatment Of Melasma","Inclusion Criteria:\n\n* Adults age 18 to 50 years Clinically diagnosed Melasma Irrespective of gender and ethnicity\n\nExclusion Criteria:\n\n* pregnant and lactating women Patients with a history of skin allergies to study medications Use of systemic steroides or anti coagulants within the last month Patients on other melasma treatments for atleast 4 weeks prior",{"count":135,"type":22},128,[137],"PHASE4","This study is to compare the efficacy of topical tranexamic acid vs topical ethyl ascorbic acid in the treatment of melasma",[29],[29],"2026-04-04",{"date":143,"type":35},"2026-04-13",{"date":145,"type":22},"2026-06-01",{"date":147,"type":22},"2026-11-30",{"name":149,"class":150},"Hayatabad Medical Complex","OTHER_GOV",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":29,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":172,"leadSponsor":174,"locationsCount":43},"100631059","comparative-evaluation-of-topical-metformin-and-topical-tranexamic-acid-in-melasma-100631059","NCT07495748","Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma","Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma Using MASI Score Reduction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18-50 years\n\n  * Clinically diagnosed facial melasma\n  * Both genders\n  * Patients willing to give informed consent\n\nExclusion Criteria:\n\n* • Pregnant or lactating women\n\n  * Patients using systemic or topical melasma treatments in the previous 4 weeks\n  * Known hypersensitivity to study medications\n  * Presence of other facial dermatoses\n  * History of photosensitivity disorders",{"count":159,"type":22},70,[25],"This randomised controlled trial aims to compare the efficacy of topical metformin (30%) and topical tranexamic acid (3%) in the treatment of melasma using reduction in the Melasma Area and Severity Index (MASI) score over 12 weeks. Melasma is a common hyperpigmentation disorder with significant cosmetic and psychological impact, and current treatments often have limitations. Both metformin and tranexamic acid have shown promising depigmenting effects through different mechanisms. A total of 70 patients will be enrolled and randomly divided into two groups. Participants will apply the assigned treatment once daily along with sunscreen and will be assessed at baseline and at 4, 8, and 12 weeks. The primary outcome is MASI score reduction, while secondary outcomes include patient-reported improvement and safety. This study seeks to provide comparative evidence for safer and more effective treatment options for melasma management.",[29],[29,164,165,166,167],"topical metformin","topical tranexamic acid","hyper-pigmentation","MASI","2026-03-24",{"date":170,"type":35},"2026-03-27",{"date":34,"type":22},{"date":173,"type":22},"2027-07-01",{"name":175,"class":73},"Foundation University Islamabad",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":29,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":81,"minAge":183,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":198,"leadSponsor":200,"locationsCount":43},"100630292","comparative-evaluation-of-topical-30-metformin-and-kligmans-regimen-in-women-with-melasma-100630292","NCT07485777","Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Women With Melasma","A Novel Approach to Melasma Management: Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Middle-Aged Women","Inclusion Criteria:\n\n* Female patients aged 35-55 years\n* Clinically diagnosed epidermal or dermal melasma (confirmed by Wood's lamp examination)\n* Fitzpatrick skin types III-V\n* Duration of melasma ≥6 months\n* No topical or systemic treatment for melasma in the past month\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Known allergy to study medications\n* Active facial dermatitis, acne, or recent cosmetic procedures","35 Years","55 Years",{"count":186,"type":22},82,[25],"It's a prospective, randomised, assessor-blinded clinical study comparing topical 30% metformin with Kligman's regimen for melasma in women aged 35-55 years at Fauji Foundation Hospital, Rawalpindi. The study seeks to ascertain which treatment yields a more significant decrease in the modified MASI score over an 8-week period and which treatment is associated with fewer adverse effects, such as erythema, burning, peeling, and post-inflammatory hyperpigmentation. A total of 82 participants will be enrolled and randomly assigned to either metformin cream or Kligman's regimen, with both groups also using sunscreen. Assessments will be done at baseline, week 4, and week 8 through mMASI scoring, photographs, and side-effect monitoring. Data will be analyzed in SPSS 26 using t-tests and chi-square testing. The study is based on evidence suggesting metformin may offer comparable efficacy with better tolerability.",[190,29],"Melasma (Facial Melasma)",[29,164,192,166,193],"kligman regimen","mMASI","2026-03-17",{"date":196,"type":35},"2026-03-20",{"date":34,"type":22},{"date":199,"type":22},"2027-06-01",{"name":175,"class":73},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":81,"minAge":19,"maxAge":82,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":210,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100627421","phase-2-evaluation-of-the-efficacy-of-oral-tranexamic-acid-and-glutathione-assisted-microneedling-in-treatment-of-melasma-100627421","NCT07448415","Evaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma","Evaluation of the Efficacy and Safety of Oral Tranexamic Acid Combined With Glutathione-assisted Microneedling Versus Each Therapy Alone in the Treatment of Melasma","Inclusion Criteria:\n\n* • female patients\n\n  * 18\u002F50 years old\n  * facial melasma\n\nExclusion Criteria:\n\n* pregnancy\n* lactation.\n* History of any bleeding,\n* clotting disorder\n* using anticoagulants\n* Chronic systemic diseases\n* patients with history of atypical parkinsonism\n* use of neuroleptics,\n* history of a seizure\n* drug addiction\n* Patients with signs of facial inflammation or infection.\n* Patients on oral contraceptive pills\n* patients with hormonal replacement therapy\n* patients on isotretinoin at the time of the study or during the past 6 months.",{"count":209,"type":22},42,[211,212],"PHASE2","PHASE3","In this study, the investigators evaluate the potential efficacy of TXA alone and microneedling assisted with glutathione alone versus combination of oral tranexamic acid and glutathione-assisted microneedling in the treatment of melasma",[29],[91,216],"glutathione","2026-02-28",{"date":219,"type":35},"2026-03-04",{"date":221,"type":22},"2026-02",{"date":223,"type":22},"2027-04",{"name":225,"class":73},"Assiut University",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":17,"sex":18,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":245,"leadSponsor":247,"locationsCount":4},"100625988","evaluation-of-efficacy-and-tolerabilty-of-melab3-serum-in-combination-of-35-glycolic-acid-peeling-compared-to-35-glycolic-acid-peeling-alone-in-various-hyperpigmentation-conditions-100625988","NCT07429786","Evaluation of Efficacy and Tolerabilty of MelaB3 Serum in Combination of 35% Glycolic Acid Peeling Compared to 35% Glycolic Acid Peeling Alone in Various Hyperpigmentation Conditions","Randomized Clinical Trial to Assess the Effectiveness and Tolerability of MELA B3 Serum in Combination With 35% Glycolic Acid Peel vs. 35% Glycolic Acid Peel for the Treatment of Various Hyperpigmentation Conditions (Melasma, Post-inflammatory Hyperpigmentation and Solar Lentigo) and Signs of Aging in a Population of Participants From the Autonomous City of Buenos Aires, Argentina.","Inclusion Criteria:\n\n1. Women and men\n2. From 30 to 70 years of age (inclusive)\n3. Good general health\n4. With any type of phototype\n5. Hyperpigmentation condition with average darkness \\> 3:\n\n   1. Epidermal or mixed melasma (determined by Wood's lamp examination at screening), mild to moderate melasma (IGA 1 or 2)\n   2. Post acne inflammatory hyperpigmentation (PIHP), mild to moderate (IGA 1 or 2) with no active acne and less than 10 inflammatory lesion on full face\n   3. Solar lentigo (SL) with a pigmentation score\\>5\n6. Willingness to protect oneself from the sun as much as possible for the duration of the study\n7. Willingness to avoid contraindicated products (irritants, other depigmenting agents)\n8. Signing of written informed consent\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding or with pregnancy plans.\n2. All contraindications for superficial peeling (for example, concomitant infectious processes or inflammatory processes that affect the skin barrier).\n3. Melasma with predominance of the pigmentary component at the dermis level, observed with Wood's light at the inclusion visit.\n4. Active acne with 10 or more inflammatory lesions.\n5. In the case of melasma, participants with recent change of contraception (less than 3 months) or less than 3 months since childbirth.\n6. Participant using irritating products (require a washout period of at least 2 weeks).\n7. Use of medications that may induce melasma, such as antiepileptics (requires a washout period of 1 month).\n8. Use of other products with depigmenting activity (requires a washout period of 1 month).\n9. Other facial dermatoses or known photosensitivity, or a pre-existing or latent dermatologic health condition and\u002For disease on the face (e.g., psoriasis, rosacea, acne, eczema, seborrheic dermatitis, severe excoriations) that, in the judgment of the investigator, are considered inappropriate for participation or may interfere with study results.\n10. Topical treatments applied to the face (requires a 2-week washout period).\n11. Scheduled facial procedures during the course of the study.\n12. Participants undergoing phototherapy (requires a 1-month washout period).\n13. Known hypersensitivity to study products.\n14. History of laser resurfacing procedures, intense pulsed light, facial radiofrequency, deep peeling, facial mesotherapy with tranexamic acid, botulinum toxin or dermal filler injections, or cosmetic procedures on the face within 6 months prior to the start of the study.\n15. Facial treatment with microdermabrasion within 6 weeks prior to study entry.\n16. Persons with visible tanning, scars, moles, excessive hair or other dermal conditions on the face that, in the judgment of the investigator, may influence the results of the study.\n17. History of skin cancer, immunosuppression or immunodeficiency disorders (including HIV infection or AIDS), or current use of immunosuppressive drugs.\n18. Uncontrolled disease such as asthma, diabetes, hypertension, hyperthyroidism or hypothyroidism. Persons with multiple health conditions may be excluded, even if controlled by diet or medication.\n19. Participation in another clinical trial within one week prior to entering this study.","30 Years","70 Years",{"count":236,"type":22},80,[25],"Randomized clinical trial to assess the effectiveness and tolerability of Mela B3 serum in combination with 35% glycolic acid peel vs. 35% glycolic acid peel for the treatment of various hyperpigmentation conditions (melasma, post-inflammatory hyperpigmentation and solar lentigo) and signs of aging in a population of participants from the Autonomous City of Buenos Aires, Argentina.",[60,29,30,240],"Peeling","2026-02-17",{"date":243,"type":35},"2026-02-24",{"date":219,"type":22},{"date":246,"type":22},"2026-06",{"name":248,"class":42},"Cosmetique Active International",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":17,"sex":81,"minAge":233,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":43},"100603485","secretome-tgf-beta-3-100603485","NCT07137130","Secretome TGF Beta 3","Development Of Adipose-Derived Mesenchymal Stem Cells Secretome (ADMSCS) Based Products From Stem Cell Conditioned Medium For Melasma Therapy","TGF Beta 3","Inclusion Criteria:\n\n* Women diagnosed with melasma.\n* Women without melasma and have areas of skin that are clinically free of lesions for SP control.\n* 30-60 years old.\n* Fitzpatrick skin type IV-V.\n* Willing to be a research subject by signing a research consent form (Informed Consent).\n\nExclusion Criteria:\n\n* Pregnant and breastfeeding women.\n* Currently using hormonal contraception or have ever used contraception hormones in the last 6 months.\n* Using topical therapy for melasma, for example corticosteroids, tretinoin, hydroquinone, and other therapies that whiten or brighten the skin in the last 2 weeks.\n* Using topical triple combination cream therapy for at least 3 months and did not show significant improvement\n* Using systemic therapy for melasma, for example antioxidants or tranexamic acid in the last 4 weeks.\n* History of superficial peeling therapy in the last 4 weeks.\n* History of deep peeling therapy, laser or mechanical abrasion in the last 6 months.\n* Using drugs that are photosensitizers such as tetracycline, phenytoin, carbamazepine, spironolactone.\n* History of blood clotting disorders or on blood thinning therapy.\n* Allergy to tranexamic acid.\n* Have other skin complaints that may interfere with the evaluation of melasma, for example post-inflammatory hyperpigmentation, Hori's nevus, Ota's nevus, pigmented contact dermatitis, and other pigmentation disorders\n* Difficulty complying with treatment.","60 Years",{"count":259,"type":22},34,[25],"A therapeutic modality currently being developed for melasma is secretome. Secretome is a bioactive molecule secreted by mesenchymal stem cells in a conditioned medium containing a large number of growth factors, cytokines, various macromolecules, and extracellular vesicles, including microvesicles and exosomes, that can stimulate various biological reactions, particularly in modulating new tissue formation. Secretome can provide a depigmenting effect by increasing the proliferation and migration of epidermal keratinocytes, which contain melanin pigment, in line with increased fibroblast synthesis.\n\nSecretomes contain various cytokines and growth factors, one of which is transforming growth factor (TGF)-β. TGF-β is primarily secreted by fibroblasts (FB) and, to a lesser extent, by keratinocytes, and plays a crucial role in regulating melanocyte function. TGF-β has been reported to inhibit cAMP\u002Fprotein kinase A signaling and induce GLI2, which then suppresses microphthalmia-associated transcription factor (MITF), a central transcription factor in melanogenesis. A study by Moon et al. in Korea examined TGF-β3. Moon et al. examined the effects of TGF-β3 on melanogenesis in human melanocytes co-cultured with skin cells irradiated with ultraviolet (UV) light, and in UV-irradiated human skin. The results showed that UVB irradiation or stem cell factor (SCF)\u002Fendothelin-1 (ET-1) increased melanogenesis. TGF-β3 effectively inhibited melanin accumulation and tyrosinase activity by downregulating the extracellular signal-regulated kinase (ERK)\u002Fmicrophthalmia-associated transcription factor (MITF) pathway. TGF-β3 increased the expression of keratinocyte differentiation markers.\n\nMechanistically, TGF-β3 inhibits melanogenesis by inhibiting MITF expression, which is regulated by ERK. TGF-β1 reduces MITF but at the risk of inducing skin fibrosis. However, in the study by Moon et al., the aforementioned TGF Beta 1 function was not found in TGF-β3. Furthermore, TGF-β3 restored skin differentiation function in UV-irradiated keratinocytes.\n\nTo date, there have been no clinical trials comparing intradermal injection of concentrated secretome with intradermal injection of concentrated secretome with the addition of TGF-β3 as a melasma therapy in Indonesia, thus encouraging researchers to conduct further research.",[29],"2025-08-15",{"date":265,"type":35},"2025-08-22",{"date":267,"type":22},"2026-02-14",{"date":269,"type":22},"2026-12-20",{"name":271,"class":73},"Indonesia University",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":17,"sex":81,"minAge":19,"maxAge":257,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":43},"100602279","efficacy-and-safety-of-a-combined-serum-containing-melasyl-10-niacinamide-hyaluronic-acid-and-hepes-100602279","NCT07121439","Efficacy and Safety of a Combined Serum Containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES","The Efficacy and Safety of a Combined Serum Containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and Hydroxyethylpiperazine Ethane Sulfonic Acid Following Low-Fluence Q-Switched Nd:YAG 1064 nm Laser Treatment for Melasma and Post-Acne Hyperpigmentation Therapy","Inclusion Criteria:\n\n* Female, aged 18-60 years.\n* Patients diagnosed with post-acne hyperpigmentation and melasma based on clinical examination and Wood's lamp evaluation, with Fitzpatrick skin types IV and V.\n* Patients visiting the Dermatology and Venereology Outpatient Clinic and scheduled to undergo QS Nd:YAG 1064 nm low-fluence laser treatment.\n\nPatients who are currently receiving or have received a priming regimen for at least two weeks prior to the laser procedure, consisting of either 2% hydroquinone cream or a serum containing Niacinamide 10%, Hyaluronic Acid, and HEPES.\n\n\\- Willing to participate in the study and provide written informed consent after receiving a complete explanation of the study procedures.\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding, or currently taking oral contraceptives at the time of evaluation.\n* History of systemic retinoid use within the past three months.\n* History of or ongoing treatment for hormonal\u002Fendocrine disorders or other severe systemic illnesses.\n* Currently undergoing immunosuppressive therapy.\n* Difficulty adhering to treatment protocols.",{"count":280,"type":22},68,[25],"The goal of this clinical trial is to evaluate the efficacy and safety of a combination serum containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES when used as a moisturizer after QS-Nd:YAG 1064 nm low-fluence laser treatment for melasma and post-acne hyperpigmentation.\n\nThe study aims to answer the following main questions:\n\n* Does the combination serum reduce hyperpigmented lesions after laser treatment for melasma and post-acne hyperpigmentation?\n* Does the serum improve skin hydration following laser therapy for melasma?\n* Is the combination serum safe for use after laser treatment, without causing irritation or adverse effects?\n\nParticipants will be female patients aged 18-60 years, clinically diagnosed with melasma or post-acne hyperpigmentation (skin types IV and V), who visit the Dermatology \\& Venereology Outpatient Clinic for QS-Nd:YAG 1064 low-fluence laser treatment. All participants will have undergone a 2-week priming period using either 2% hydroquinone cream or the test serum prior to laser treatment. Written informed consent is required.\n\nParticipants will be randomly assigned to receive either the test serum or 2% hydroquinone cream based on a coded allocation. The product will be applied twice daily after facial cleansing, and sunscreen will be used 15 minutes before outdoor activities. Treatment lasts for 2 weeks, with participants recording application times and any adverse effects in a diary. Evaluations-including facial photography, mMASI, mexameter, dermoscopy, Wood's lamp, and PAHPI-will be conducted at baseline and at 1, 2, and 4 weeks post-laser. Erythema and subjective assessment (VAS) will be performed 15 minutes after the laser procedure.",[29,284],"Post-acne Hyperpigmentation","2025-08-06",{"date":287,"type":35},"2025-08-13",{"date":289,"type":22},"2025-09-15",{"date":291,"type":22},"2025-12-01",{"name":293,"class":73},"Dr.dr.Irma Bernadette, SpKK (K)",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":300,"targetDuration":4,"studyType":23,"phases":302,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":43},"100597566","comparative-efficacy-of-resveratrol-1--gel-and-trichloroacetic-acid-20-in-treatment-of-melasma-a-split-face-study-100597566","NCT07060157","Comparative Efficacy of Resveratrol 1 % Gel and Trichloroacetic Acid 20% in Treatment of Melasma: A Split-face Study","Inclusion Criteria:\n\n* • Age: 18-50 years old.\n\n  * Pattern of melasma: Bilateral symmetrical facial melasma of any pattern.\n  * Fitzpatrick skin phototypes: Types III, IV and V.\n\nExclusion Criteria:\n\n* Pregnancy and lactation.\n\n  * Patients taking oral contraceptive pills, hormonal replacement therapy or treatment for chronic illness at the time of the study or during the past 6 months.\n  * Coexistence of diseases associated with hyperpigmentation such as Addison disease.\n  * History of Scarring and keloid tendency\n  * Active skin infections as active HSV.\n  * Previous history of post- inflammatory hyperpigmentation.",{"count":301,"type":22},41,[25],"1. To evaluate the efficacy and safety of topical resveratrol 1 % gel in treatment of melasma.\n2. To compare between the efficacy of topical resveratrol 1 %gel versrs chemical peeling with TCA 20% in melasma.",[29],[306],"resveratrol in melasma","2025-07-09",{"date":309,"type":35},"2025-07-11",{"date":311,"type":22},"2025-07-22",{"date":313,"type":22},"2027-06-08",{"name":225,"class":73},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":257,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":334,"locationsCount":43},"100533128","stem-cell-derived-exosomes-in-the-treatment-of-melasma-and-its-percutaneous-penetration-100533128","NCT06221787","Stem Cell Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration","Inclusion Criteria:\n\n\\- Patients diagnosed with chloasma who meet the clinical diagnostic standards and efficacy standards (revised version) of chloasma and have skin lesions on the face.\n\nIt is hoped that exosomes combined with 1565 non-ablative fractional laser, blue aurora or micro-needle can improve facial chloasma.\n\nFully understand and understand the content and significance of this study, implementation plan, possible benefits, risks and countermeasures, rights and obligations of subjects (including privacy protection, free withdrawal), willing to participate in this clinical study and able to cooperate well, Those who signed the informed consent form.\n\nExclude post-inflammatory pigmentation, malar brown-green nevus, Riehl's melanosis, pigmented lichen planus and other skin diseases.\n\nSubjects who agree not to use other cosmetic treatments related to the study during the study period.\n\nExclusion Criteria:\n\n1. Patients who refuse to sign the informed consent form to participate in the trial;\n2. Those with a history of important organ diseases, or a history of autoimmune diseases or immune dysfunction;\n3. Abnormal coagulation function, current use of anticoagulants, thrombophilia and history of familial genetic diseases;\n4. Pregnant or lactating women;\n5. Patients taking oral contraceptives or hormone replacement therapy during the study period or within the past 12 months;\n6. Patients with scar constitution;\n7. Active skin infection;\n8. Those who have a history of multiple severe allergies, a history of hereditary allergies, photosensitivity or photosensitivity drugs, such as sulfa drugs and tetracyclines, those who are allergic to local anesthetics and those who are allergic to lidocaine components, and those who plan to undergo detoxification during the study Allergy healer;\n9. History of post-inflammatory pigmentation;\n10. Those who have received treatment for chloasma in the past;\n11. Those who have undergone chemical peeling, dermabrasion or other skin resurfacing on their face in the past;\n12. Patients who are participating in other clinical studies;\n13. Other reasons that the researcher considers unsuitable for clinical investigators.",{"count":236,"type":22},[25],"Melasma is a refractory skin disease due to its complex pathogenesis and difficult treatment. Studies have found that human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) could serve as a novel cell-free therapeutic strategy in regenerative and aesthetic medicine. It could potentially treat melasma, but the skin barrier is a challenge. This study aims to explore the safety and efficacy of hUCMSC-Exos in the treatment of melasma and means to promote its percutaneous penetration.",[29],[29,326,327],"Stem cell-derived exosomes","Percutaneous Penetration","2025-06-29",{"date":330,"type":35},"2025-07-02",{"date":332,"type":35},"2022-04-01",{"date":34,"type":22},{"name":335,"class":73},"Fujian Medical University Union Hospital",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":257,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":4},"100588514","phase-2-topical-metformin-versus-topical-ketotifen-in-melasma-treatment-100588514","NCT06942390","Topical Metformin Versus Topical Ketotifen in Melasma Treatment","Topical Metfotmin Versus Topical Ketotifen (Alone or in Combination With Microneddling)in Melasma Treatment :Comparative Split Face Study","Inclusion Criteria:\n\n* Female adults of 18 years and above with bilateral melasma .\n* Clinical diagnosis of melasma.\n* Mental capacity to give informed consent.\n\nExclusion Criteria:\n\n* Pregnant or nursing women.\n* Current use of hormonal birth control medication or any hormonal therapy.\n* Current or previous treatment by depigmenting agents within 3 months\n* History of laser or MN to the face within 3 months of study enrollment.\n* Patients with poor wound healing, recurrent herpes simplex and current skin infection (facial warts, molluscum contagiosum) and history of hypertropic scar\u002Fkeloids.\n* Photosensitivity.\n* Patients with unrealistic expectations.",{"count":344,"type":22},60,[211],"The study aims to evaluate and compare the efficacy and safety of a new formulation of topical metformin (nanoparticles) versus topical ketotifen (nanoparticles), both alone and combined with micro-needling, for the treatment of melasma. It is a double-blinded, randomized, split-face controlled clinical study involving 102 female patients diagnosed with bilateral melasma.",[29],"2025-04-16",{"date":350,"type":35},"2025-04-24",{"date":352,"type":22},"2025-06-01",{"date":354,"type":22},"2026-10-30",{"name":225,"class":73},{"id":357,"slug":358,"hasResults":11,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":81,"minAge":363,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":368,"conditions":369,"keywords":370,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":43},"100581071","phase-1-oral-metformin-for-treating-melasma-in-latin-american-women-100581071","NCT06845540","Oral Metformin for Treating Melasma in Latin American Women","Oral Metformin in the Treatment of Melasma: a Prospective Trial in Latin American Women","Inclusion Criteria: Latin American women aged 21 years or older, diagnosed epidermal or mixed melasma\n\nExclusion Criteria: pregnancy, breastfeeding, use of hydroquinone or tretinoin within 2 months before the study, or undergoing laser treatment, peels, microdermabrasion, or microneedling within 2 months of the study. Patients with a history of renal or liver disease, metformin allergy, diabetes, hypoglycemia, or those on medications that could interact with metformin will also be excluded.","21 Years",{"count":365,"type":22},30,[367,211],"PHASE1","The goal of this clinical trial is to learn if metformin can treat melasma in Latin American women. The main question it aims to answer is:\n\n\\- Can metformin help reduce the dark patches of melasma?\n\nResearchers will test two different doses of metformin (500 mg and 1000 mg) to see if either one helps improve melasma.\n\nParticipants will:\n\n* Take a metformin pill every day for three months.\n* Go to the clinic twice: once at the beginning and once at the end of the study.\n* Get a phone call from the researchers to check how they're doing and ask about any changes or side effects.",[29],[371,372],"melasma","metformin","2025-02-19",{"date":375,"type":35},"2025-02-25",{"date":377,"type":22},"2025-02-20",{"date":379,"type":22},"2025-05-30",{"name":381,"class":73},"University of Puerto Rico",{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":17,"sex":81,"minAge":233,"maxAge":388,"enrollmentInfo":389,"targetDuration":4,"studyType":23,"phases":391,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":43},"100576081","comparison-of-effectiveness-and-safety-of-triple-combination-cream-of-fucinolone-acetonide-001-hydroquinone-4-tretinoin-005-with-mometasone-furoate-01-hydroquinone-4-tretinoin-005-in-the-treatment-of-melasma-100576081","NCT06780644","Comparison of Effectiveness and Safety of Triple Combination Cream of Fucinolone Acetonide 0.01%, Hydroquinone 4%, Tretinoin 0.05% with Mometasone Furoate 0.1%, Hydroquinone 4%, Tretinoin 0.05% in the Treatment of Melasma","Inclusion Criteria:\n\n* Women\n* Diagnosed with melasma based on clinical and Wood's lamp examination\n* 30-59 years old\n* Skin type IV or V\n\nExclusion Criteria:\n\n* Plan to be pregnant and breastfeeding women during the study period ( 12 weeks)\n* using or have used hormonal contraception in the last 6 months, or plan to use hormonal contraception during the study period (12 weeks)\n* Using topical melasma treatments such as corticosteroids, tretinoin, hydroquinone, and other skin whitening or lightening treatments in at least the last 2 weeks.\n* Have used topical therapy for melasma i.e. triple combination cream for at least 3 months and showed no significant improvement.\n* Using systemic therapy for melasma, e.g. antioxidants, tranexamic acid in at least the last 4 weeks.\\*\n* History of eppeeling, laser or mechanical abrasion on the face in the last 6 months.\\*\n* Using photosensitizer drugs such as tetracycline, phenytoin, carbamazepine, and spironolactone in at least the last 4 weeks.\n* Having other skin complaints that may interfere with the evaluation of melasma such as post-inflammatory hyperpigmentation, Hori nevus, Ota nevus, pigmented contact dermatitis, and other pigmentation disorders.\n* Difficulty in adherence to treatment such as long distance from home, work schedules, and busy activities.","59 Years",{"count":390,"type":22},56,[25],"This Research is a clinical study with a single-blind randomized controlled trial of evaluators. Clinical trial Randomized Controlled Trial (RCT) design that compares the use of a triple combination cream of flucinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05% with a triple cream combination of mometasone furoate 0.1%, hydroquinone 4%, tretinoin 0.05% in melasma therapy in RSCM-FKUI.\n\nThis study aims to Assess the effectiveness and safety of Triple Combination Cream of Fucinolone Acetonide 0.01%, Hydroquinone 4%, Tretinoin 0.05% with Mometasone Furoate 0.1%, Hydroquinone 4%, Tretinoin 0.05% in melasma patients",[29],"2025-01-13",{"date":396,"type":35},"2025-01-17",{"date":398,"type":22},"2025-02-17",{"date":400,"type":22},"2025-09-01",{"name":271,"class":73},{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":257,"enrollmentInfo":408,"targetDuration":4,"studyType":23,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":419,"leadSponsor":420,"locationsCount":43},"100574752","clinical-evaluation-and-study-of-the-efficacy-of-a-centella-asiatica-infused-facial-mask-on-discosmetic-dermatosis-100574752","NCT06763367","Clinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis","Inclusion Criteria:\n\n1. Meet mild to moderate rosacea, acne diagnostic criteria; Meet the diagnostic criteria for melasma;\n2. Over 18 years of age;\n3. Be able to follow the treatment rules of the study and be followed for 8 weeks;\n4. Informed consent; 5There were no significant cardiac, liver, kidney, gastrointestinal, neurological, psychiatric, or metabolic disorders\n\n6.No medication was used within 1 month\n\nExclusion Criteria:\n\n1. Currently pregnant, planning to become pregnant or breastfeeding;\n2. Documented hypersensitivity to any active ingredient or excipient included in the study drug, or a history of adverse reactions to cosmetic products;\n3. Participate in other clinical studies within 3 months before the start of the study;\n4. Frequent use of Chinese medicine, sleeping pills, sedatives, anti-anxiety drugs or potentially addictive substances;\n5. Present with concomitant skin conditions that may confuse the clinical assessment of rosacea, melasma, seborrheic dermatitis or pose a risk to participants, or have a history of severe skin conditions;\n6. Normal use of relevant treatment (including intense pulsed light, pulsed fuel laser, oral and topical tranexamic acid, oral tetracycline antibiotics, oral compound glycyrrhizin and other anti-inflammatory drugs)\n7. Patients with incomplete observation data, incomplete course of treatment and inability to take drugs as prescribed by doctors were removed",{"count":365,"type":22},[25],"The purpose of this study was to investigate the efficacy and safety of repairing facial mask containing Asiaticum asiatica in treating disjunctive skin diseases. A multi-center randomized double-blind self-half face control method was used. A computer-generated randomization method was used. Each cheek was randomly assigned to receive the snow glycoside mask and the control group.",[412,413,414,29],"Rosacea","Acne","Centella","2025-01-02",{"date":417,"type":35},"2025-01-08",{"date":417,"type":22},{"date":147,"type":22},{"name":421,"class":73},"Nanjing First Hospital, Nanjing Medical University",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":444},"100551027","phase-2-randomized-study-using-sm-030-gel-for-adults-with-melasma-100551027","NCT06454747","Randomized Study Using SM-030 Gel for Adults With Melasma","A Randomized, Observer-Blinded, Placebo-Controlled Study on the Safety and Efficacy of Twice Daily Application of SM-030 Gel 0.64% Vs. SM-030 Gel 0.08% Vs. Placebo Gel in Adults With Melasma","Inclusion Criteria\n\nSubjects must meet all of the following criteria to be included in the study:\n\n1. Subjects must meet all of the following criteria to be included in the study:\n2. Male or Female age 18-65 with Fitzpatrick skin type II through V and a clinical diagnosis of Melasma\n3. Subjects with moderate to severe Melasma using the following guidelines:\n\n1\\. Stable (unchanged per subject reporting) melasma for at least 3 months 2. Macular lesions, neither depressed nor atrophic 3. Melasma Severity Score of at least 2 (hyperpigmentation at least moderately darker than surrounding normal skin 3. Ability to understand, agree to, and sign the study informed consent form (ICF).\n\n4\\. For female or childbearing subjects, they must be on an agreeable form of birth control (oral contraceptive therapies, estrogen replacement therapies, other non-oral hormonal therapies, IUDs, be abstinent, or have a vasectomized partner) and who have not added and\u002For changed the method of birth control in the last 6 months, and have no intention of adjusting or changing the method of birth control 5. Agree to discontinue all agents used to treat hyperpigmentation, aging or exfoliate the skin during the course of the study. Makeup and moisturizers are permitted.\n\n6\\. Agree not to change their sun exposure at work, home, or leisure and apply study supplied sunscreen daily.\n\n7\\. Technical ability and willingness to apply Investigational product. 8. Willing to allow digital photos of treatment and comparison areas to be taken and stored.\n\n9\\. Willing to apply study-supplied mineral sunscreen, moisturizer, and cleanser to the face daily throughout the duration of the study\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will be excluded in the study:\n\n1. Positive urine pregnancy test, pregnant, lactating, or female of childbearing potential who does not agree to use an active method of birth control for the duration of the study.\n2. Conditions at baseline that would interfere with evaluation of UV-tanned skin, especially other pigmentary disorders including, but not limited to vitiligo affecting the treatment and comparison sites.\n3. Severe photodamage as assessed by the 10-point photo damage assessment scale (Griffiths et al., 1992); (McKenzie et al., 2011).\n4. Presence of known concomitant diseases associated with the development of hyperpigmentation (e.g., thyroid, liver, adrenal).\n5. Current tanning booth exposure or any kind of phototherapy within 3 months of Screening.\n6. Current or past use of monobenzyl ether to depigment skin.\n7. Use of the following topical preparations within a 28-day washout period: topical corticosteroids, topical bleaching products (hyroquinone, niacinamide, kojic acid, ascorbic acid, chemical peels, topical tranexamic acid (TXA)), UV light therapy and sunbathing, topical retinoids.\n8. Use of the following systemic agents within the specified washout periods:\n\n1\\. Systemic corticosteroids (28 days) 2. Systemic cyclosporine, interferon (6 months) 3. Systemic acitretin, etretinate, isotretinoin (6 months) 4. Systemic methotrexate (6 months) 5. Systemic tranexamic acid (TXA) 6. Systemic photoallergic, phototoxic, and or photosensitizing drugs (6 months including psoralens, sulfonamide drugs, tetracycline antibiotics, thiazide diuretics, phenothiazines, coal tar and derivatives, and tricyclic antidepressants, chlorpromazine, benoxaprofen, piroxicam, nalidixic acid, procainamide, phenytoin, antimalarial medications, some cystostatic agents)\n\n9\\. Laser (ablative or non-ablative), microneedling, PRP, or light-based treatment of the treatment areas within 3 months of Screening.\n\n10\\. Any dermatological conditions within the designated application area that could interfere with clinical evaluations or any disease state or physical condition which might expose the subject to an unacceptable risk by study participation (neurodermatitis, eczema, psoriasis, atrophy, rosacea, seborrheic dermatits, etc.).\n\n11\\. Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy (see Exclusion criteria 6, 7, and 8).\n\n12\\. Known high daily exposure to the sun (\\>4 hours of sun exposure through work or daily activities) and\u002For frequent sunbathing\u002FUV tanning.\n\n13\\. Unwilling to discontinue applying any prescription or over the counter (OTC) topical product creams and ointments, other than makeup and moisturizers, on treatment area(s) at Baseline through their last day of study.\n\n14\\. Treatment of any type of cancer within 6 months of Screening, with the exception of superficial skin cancers such as basal cell or squamous cell carcinoma outside of treatment area.\n\n15\\. Known allergy to any of the Investigational product(s) or any components in the Investigational product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure.\n\n16\\. Unable to meet the study attendance requirements.\n\n17\\. Any history of psychiatric disease or history of alcohol or drug abuse that would interfere with the ability to comply with the study protocol.\n\n18\\. Participation in any other trial of an investigational drug or device within 30 days prior to enrollment or participation in a research study concurrent with this study.","65 Years",{"count":431,"type":22},138,[211],"Brief Summary This is a phase 2b, observer-blinded, randomized study that will evaluate the safety and efficacy of topically applied SM-030 gel 0.64% and SM-030 gel 0.08% compared against placebo gel in healthy adult male and female subjects with Melasma. The study will be comprised of a 12-week twice daily dosing period and a 4-week additional safety follow-up period. Approximately 138 subjects who meet the eligibility criteria, notably with a clinical diagnosis of Melasma will be randomized in a 3:2:1 ratio to one of three treatment arms: SM-030 gel 0.64% (N=69), Placebo gel (N=46), or SM-030 gel 0.08% (N=23). Subjects will be competitively enrolled in Mexico and El Salvador across 5 sites (4 sites in Mexico and 1 in El Salvador). Subjects will be assessed for safety and efficacy at each visit.",[29],"2024-12-10",{"date":437,"type":35},"2024-12-13",{"date":439,"type":35},"2024-06-27",{"date":441,"type":22},"2025-10",{"name":443,"class":42},"DermBiont, Inc.",2,{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":23,"phases":453,"briefSummary":454,"conditions":455,"keywords":457,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":43},"100511654","the-use-of-image-based-computer-gradings-in-the-analysis-of-acne-rosacea-melasma-and-seborrheic-dermatitis-100511654","NCT05942248","The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis","Inclusion Criteria:\n\n* Adults with acne, rosacea, melasma or seborrheic dermatitis\n\nExclusion Criteria:\n\n* Prisoners\n* Adults unable to consent\n* Artificial facial markings on day of facial photography (such as piercings and tattoos) that may interfere with imaging in the opinion of the investigator",{"count":452,"type":22},150,[25],"The study is conducted to determine if image-based computer grading can of acne, melasma, rosacea and seborrheic dermatitis correlate well to expert based clinical severity grading.",[413,29,412,456],"Seborrheic Dermatitis",[458,459],"Artificial Intelligent","Skin","2024-08-26",{"date":462,"type":35},"2024-08-27",{"date":464,"type":35},"2023-06-06",{"date":466,"type":22},"2025-02-28",{"name":468,"class":42},"Integrative Skin Science and Research",{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":17,"sex":81,"minAge":19,"maxAge":429,"enrollmentInfo":476,"targetDuration":4,"studyType":23,"phases":477,"briefSummary":478,"conditions":479,"keywords":480,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":43},"100555756","anti-pigmenting-effect-of-a-routine-of-facial-products-in-subjects-with-melasma-100555756","NCT06516224","Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma","Evaluation of the Efficacy of the Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma","Inclusion Criteria:\n\n* 18-65 years\n* Phototype II-V\n* 50% with sensitive skin (declarative);\n* Subjects should be affected by well defined symmetrical (on both sides of the face) epidermal melasma (clinically diagnosed under Wood's light examination) lasting since more than a year\n\nExclusion Criteria:\n\n* Subjects under topical or systemic retinoids;\n* Subjects having used topical tretinoin within 3 months or topical hydroquinone within 6 months prior to inclusion;\n* Subjects under systemic immunosuppressants and considered immune compromised\n* Subjects under active treatment of melasma (including topicals or procedures) within the last 3 months\n* Pregnant women and\u002For breastfeeding women\n* Subjects with a recent change in contraception (since less than 6 months);\n* Subjects known allergy to any component of tested product;\n* Subjects not presenting with the conditions needed to comply with the protocol;\n* Subjects without any other dermatological conditions on the face\n* Subject under menopause phase with hormonal replace therapy\n* Subjects in the initial phase, change or discontinuation of hormonal treatment (estroprogesterone, cyproteron acetate, androgenic...) in the last 3 months;\n* Subjects currently using any medication, which in the opinion of the investigator, may affect the evaluation of the study product, or place the subject at undue risk.\n* Subjects unable to give their informed consent.",{"count":452,"type":22},[25],"This 6 month, comparative study assesses the benefit of a dermocosmetic regimen (Serum B3 + B3 retinol night cream) for 6 months compared to hydroquinone 4% (the gold standard in hyperpigmentation) followed by the dermocosmetic regimen for 3 months or the Kligman Trio for 3 months followed by the dermocosmetic regimen for 3 months in adult women with melasma on the face.",[29],[371,481],"hyperpigmentation","2024-07-18",{"date":484,"type":35},"2024-07-23",{"date":486,"type":22},"2024-07-15",{"date":488,"type":22},"2025-01-31",{"name":248,"class":42},{"id":491,"slug":492,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":17,"sex":81,"minAge":233,"maxAge":257,"enrollmentInfo":495,"targetDuration":4,"studyType":23,"phases":497,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":444},"100555771","development-of-products-based-on-secretom-from-stem-cell-conditioned-medium-for-melasma-therapy-100555771","NCT06516419","Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy",{"count":496,"type":22},90,[25],"This research is a clinical study with a single-blind randomized clinical trial design (randomized controlled trial) in RSCM-FKUI\n\nThis study aims to Assess the effectiveness and safety of intradermal concentrated secretome injection therapy, triple combination cream, and intradermal tranexamic acid injection in melasma patients, determine the quality of life profile of melasma patients after triple combination cream therapy in melasma therapy, and determine SOD levels in melasma patients.\n\nThis research will be attended by 90 research subjects",[29],{"date":501,"type":35},"2024-07-24",{"date":503,"type":35},"2024-02-13",{"date":505,"type":22},"2025-03-30",{"name":293,"class":73}]